Market research
MGNX MacroGenics Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 261M
- P/E ratio
- Not available
- Analyst target
- 7.25
- Dividend yield
- Not available
- Beta
- 1.22
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US5560991094
- Market cap
- 261M
- P/E ratio
- Not available
- Analyst target
- 7.25
- Dividend yield
- Not available
- Beta
- 1.22
About
About MacroGenics Inc
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the MGNX discussion.
5 years, 4 months ago
MacroGenics, Inc is currently in a long term uptrend where the price is trading 11.4% above its 200 day moving average.
From a valuation standpoint, the stock is 98.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 16.2.
MacroGenics, Inc's total revenue rose by 109.2% to $53M since the same quarter in the previous year.
Its net income has increased by 100.0% to $-2K since the same quarter in the previous year.
Finally, its free cash flow grew by 76.9% to $-9M since the same quarter in the previous year.
Based on the above factors, MacroGenics, Inc gets an overall score of 5/5.